Top Markets
Coin of the day
Evaxion Biotech A/S Evaxion Biotech A/S

Evaxion Biotech A/S

EVAX
Clasificación en acciones #29742
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to... Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Precio por acción
$3.15
Última sincronización: 2026-08-18
Capitalización bursátil
$19.90M
Cambio (1 día)
0.64%
Cambio (1 año)
3.62%
País
DK
Comercio Evaxion Biotech A/S (EVAX)

Categoría

Ganancias de Evaxion Biotech A/S (EVAX)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Evaxion Biotech A/S, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Evaxion Biotech A/S desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
$-3.09B -
US
- -
CH